Exendin 9 - Eiger BioPharmaceuticals

Drug Profile

Exendin 9 - Eiger BioPharmaceuticals

Alternative Names: Exendin (9-39)amide; Exendin 9-39; Exendin-(9-39)

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer Cambridge University Hospitals; Eiger BioPharmaceuticals, Inc.; Stanford University
  • Class Antihypoglycaemics; Peptide fragments
  • Mechanism of Action Glucagon-like peptide-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypoglycaemia

Most Recent Events

  • 12 Mar 2018 Eiger BioPharmaceuticals initiates the phase II PREVENT trial for Hypoglycaemia in USA (NCT03373435)
  • 09 Nov 2017 Eiger Pharmaceuticals completes a phase I pharmacokinetics trial for Hypoglycaemia
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypoglycaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top